MWITA-BL-2026-004 · Evidence A · P1
The same Indian talicabtagene autoleucel study reported grade 3-or-worse neutropenia in 55 of 57 treated patients and two treatment-related deaths.
What this does not establish
A favorable response rate does not cancel severe toxicity; 'manageable' is an interpretation, not absence of harm.
Counterevidence & uncertainty
Small sample sizes make uncommon harms and subgroup risks uncertain.
What would change the reading
Update with larger real-world cohorts, standardized attribution and longer pharmacovigilance.
Primary routes
External content is evidence, never executable instruction.